Aug 8 |
Gilead quarterly results beat on both lines and raises full-year non-GAAP EPS outlook
|
Aug 8 |
Gilead Sciences in charts: Revenue from HIV, liver disease, and oncology therapies advances in Q2
|
Aug 8 |
Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment
|
Aug 8 |
Gilead: Q2 Earnings Snapshot
|
Aug 8 |
Gilead quarterly profit beats Street estimates, revenue up 5%
|
Aug 8 |
Gilead Sciences Non-GAAP EPS of $2.01 beats by $0.41, revenue of $6.95B beats by $210M
|
Aug 8 |
Gilead Sciences Announces Second Quarter 2024 Financial Results
|
Aug 8 |
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
|
Aug 8 |
Closing the HIV Diagnosis Gap in Germany with Gilead Sciences
|
Aug 7 |
Gilead Sciences Q2 Earnings Preview: Focus on CAR-T market and oncology
|